CymaBay Therapeutics
(NASDAQ:CBAY)
2.82
0.23[8.88%]
At close: Jun 24
2.68
-0.1400[-4.96%]
After Hours: 6:29PM EDT
Day High/Low2.33 - 2.82
52 Week High/Low1.67 - 4.83
Open / Close2.61 / 2.82
Float / Outstanding71.6M / 84.7M
Vol / Avg.10.4M / 738.4K
Mkt Cap238.8M
P/E-
50d Avg. Price2.19
Div / Yield-
Payout Ratio-
EPS-0.32
Total Float71.6M

CymaBay Therapeutics (NASDAQ:CBAY), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$10.00

Lowest Price Target1

$8.00

Consensus Price Target1

$9.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20000

Analyst Firms Making Recommendations1

  • B. Riley Securities
  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for CymaBay Therapeutics

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

date
Upside/Downside
Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
No Data

CymaBay Therapeutics Questions & Answers

Q
What is the target price for CymaBay Therapeutics (CBAY)?
A

The latest price target for CymaBay Therapeutics (NASDAQ: CBAY) was reported by B. Riley Securities on May 18, 2022. The analyst firm set a price target for $8.00 expecting CBAY to rise to within 12 months (a possible 183.69% upside). 4 analyst firms have reported ratings in the last year.

Q
What is the most recent analyst rating for CymaBay Therapeutics (CBAY)?
A

The latest analyst rating for CymaBay Therapeutics (NASDAQ: CBAY) was provided by B. Riley Securities, and CymaBay Therapeutics maintained their buy rating.

Q
When is the next analyst rating going to be posted or updated for CymaBay Therapeutics (CBAY)?
A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CymaBay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CymaBay Therapeutics was filed on May 18, 2022 so you should expect the next rating to be made available sometime around May 18, 2023.

Q
Is the Analyst Rating CymaBay Therapeutics (CBAY) correct?
A

While ratings are subjective and will change, the latest CymaBay Therapeutics (CBAY) rating was a maintained with a price target of $10.00 to $8.00. The current price CymaBay Therapeutics (CBAY) is trading at is $2.82, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.